American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I--evidence assessment.

Laxmaiah Manchikanti, Salahadin Abdi, Sairam Atluri, Carl C. Balog, Ramsin M. Benyamin, Mark V. Boswell, Keith R. Brown, Brian M. Bruel, David A. Bryce, Patricia A. Burks, Allen W. Burton, Aaron K. Calodney, David L. Caraway, Kimberly A. Cash, Paul J. Christo, Kim S. Damron, Sukdeb Datta, Timothy R. Deer, Sudhir Diwan, Ike EriatorFrank J E Falco, Bert Fellows, Stephanie Geffert, Christopher G. Gharibo, Scott E. Glaser, Jay S. Grider, Haroon Hameed, Mariam Hameed, Hans Hansen, Michael E. Harned, Salim M. Hayek, Standiford Helm, Joshua A. Hirsch, Jeffrey W. Janata, Alan D. Kaye, Adam M. Kaye, David S. Kloth, Dhanalakshmi Koyyalagunta, Marion Lee, Yogesh Malla, Kavita N. Manchikanti, Carla D. McManus, Vidyasagar Pampati, Allan T. Parr, Ramarao Pasupuleti, Vikram B. Patel, Nalini Sehgal, Sanford M. Silverman, Vijay Singh, Howard S. Smith, Lee T. Snook, Daneshvari R. Solanki, Deborah H. Tracy, Ricardo Vallejo, Bradley W. Wargo, Society of Interventional Pain Physicians American Society of Interventional Pain Physicians

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Opioid abuse has continued to increase at an alarming rate since the 1990 s. As documented by different medical specialties, medical boards, advocacy groups, and the Drug Enforcement Administration, available evidence suggests a wide variance in chronic opioid therapy of 90 days or longer in chronic non-cancer pain. Part 1 describes evidence assessment. The objectives of opioid guidelines as issued by the American Society of Interventional Pain Physicians (ASIPP) are to provide guidance for the use of opioids for the treatment of chronic non-cancer pain, to produce consistency in the application of an opioid philosophy among the many diverse groups involved, to improve the treatment of chronic non-cancer pain, and to reduce the incidence of abuse and drug diversion. The focus of these guidelines is to curtail the abuse of opioids without jeopardizing non-cancer pain management with opioids. 1) There is good evidence that non-medical use of opioids is extensive; one-third of chronic pain patients may not use prescribed opioids as prescribed or may abuse them, and illicit drug use is significantly higher in these patients. 2) There is good evidence that opioid prescriptions are increasing rapidly, as the majority of prescriptions are from non-pain physicians, many patients are on long-acting opioids, and many patients are provided with combinations of long-acting and short-acting opioids. 3) There is good evidence that the increased supply of opioids, use of high dose opioids, doctor shoppers, and patients with multiple comorbid factors contribute to the majority of the fatalities. 4) There is fair evidence that long-acting opioids and a combination of long-acting and short-acting opioids contribute to increasing fatalities and that even low-doses of 40 mg or 50 mg of daily morphine equivalent doses may be responsible for emergency room admissions with overdoses and deaths. 5) There is good evidence that approximately 60% of fatalities originate from opioids prescribed within the guidelines, with approximately 40% of fatalities occurring in 10% of drug abusers. 6) The short-term effectiveness of opioids is fair, whereas the long-term effectiveness of opioids is limited due to a lack of long-term (> 3 months) high quality studies, with fair evidence with no significant difference between long-acting and short-acting opioids. 7) Among the individual drugs, most opioids have fair evidence for short-term and limited evidence for long-term due to a lack of quality studies. 8) The evidence for the effectiveness and safety of chronic opioid therapy in the elderly for chronic non-cancer pain is fair for short-term and limited for long-term due to lack of high quality studies; limited in children and adolescents and patients with comorbid psychological disorders due to lack of quality studies; and the evidence is poor in pregnant women. 9) There is limited evidence for reliability and accuracy of screening tests for opioid abuse due to lack of high quality studies. 10) There is fair evidence to support the identification of patients who are non-compliant or abusing prescription drugs or illicit drugs through urine drug testing and prescription drug monitoring programs, both of which can reduce prescription drug abuse or doctor shopping. DISCLAIMER: The guidelines are based on the best available evidence and do not constitute inflexible treatment recommendations. Due to the changing body of evidence, this document is not intended to be a "standard of care."

Original languageEnglish (US)
JournalPain Physician
Volume15
Issue number3 Suppl
StatePublished - Jul 2012
Externally publishedYes

Fingerprint

Opioid Analgesics
Guidelines
Physicians
Pain
Prescription Drugs
Street Drugs
Prescriptions
Prescription Drug Misuse
Specialty Boards
Therapeutics
Drug Prescriptions
Drug Monitoring

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Manchikanti, L., Abdi, S., Atluri, S., Balog, C. C., Benyamin, R. M., Boswell, M. V., ... American Society of Interventional Pain Physicians, S. O. I. P. P. (2012). American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I--evidence assessment. Pain Physician, 15(3 Suppl).

American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain : Part I--evidence assessment. / Manchikanti, Laxmaiah; Abdi, Salahadin; Atluri, Sairam; Balog, Carl C.; Benyamin, Ramsin M.; Boswell, Mark V.; Brown, Keith R.; Bruel, Brian M.; Bryce, David A.; Burks, Patricia A.; Burton, Allen W.; Calodney, Aaron K.; Caraway, David L.; Cash, Kimberly A.; Christo, Paul J.; Damron, Kim S.; Datta, Sukdeb; Deer, Timothy R.; Diwan, Sudhir; Eriator, Ike; Falco, Frank J E; Fellows, Bert; Geffert, Stephanie; Gharibo, Christopher G.; Glaser, Scott E.; Grider, Jay S.; Hameed, Haroon; Hameed, Mariam; Hansen, Hans; Harned, Michael E.; Hayek, Salim M.; Helm, Standiford; Hirsch, Joshua A.; Janata, Jeffrey W.; Kaye, Alan D.; Kaye, Adam M.; Kloth, David S.; Koyyalagunta, Dhanalakshmi; Lee, Marion; Malla, Yogesh; Manchikanti, Kavita N.; McManus, Carla D.; Pampati, Vidyasagar; Parr, Allan T.; Pasupuleti, Ramarao; Patel, Vikram B.; Sehgal, Nalini; Silverman, Sanford M.; Singh, Vijay; Smith, Howard S.; Snook, Lee T.; Solanki, Daneshvari R.; Tracy, Deborah H.; Vallejo, Ricardo; Wargo, Bradley W.; American Society of Interventional Pain Physicians, Society of Interventional Pain Physicians.

In: Pain Physician, Vol. 15, No. 3 Suppl, 07.2012.

Research output: Contribution to journalArticle

Manchikanti, L, Abdi, S, Atluri, S, Balog, CC, Benyamin, RM, Boswell, MV, Brown, KR, Bruel, BM, Bryce, DA, Burks, PA, Burton, AW, Calodney, AK, Caraway, DL, Cash, KA, Christo, PJ, Damron, KS, Datta, S, Deer, TR, Diwan, S, Eriator, I, Falco, FJE, Fellows, B, Geffert, S, Gharibo, CG, Glaser, SE, Grider, JS, Hameed, H, Hameed, M, Hansen, H, Harned, ME, Hayek, SM, Helm, S, Hirsch, JA, Janata, JW, Kaye, AD, Kaye, AM, Kloth, DS, Koyyalagunta, D, Lee, M, Malla, Y, Manchikanti, KN, McManus, CD, Pampati, V, Parr, AT, Pasupuleti, R, Patel, VB, Sehgal, N, Silverman, SM, Singh, V, Smith, HS, Snook, LT, Solanki, DR, Tracy, DH, Vallejo, R, Wargo, BW & American Society of Interventional Pain Physicians, SOIPP 2012, 'American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I--evidence assessment.', Pain Physician, vol. 15, no. 3 Suppl.
Manchikanti, Laxmaiah ; Abdi, Salahadin ; Atluri, Sairam ; Balog, Carl C. ; Benyamin, Ramsin M. ; Boswell, Mark V. ; Brown, Keith R. ; Bruel, Brian M. ; Bryce, David A. ; Burks, Patricia A. ; Burton, Allen W. ; Calodney, Aaron K. ; Caraway, David L. ; Cash, Kimberly A. ; Christo, Paul J. ; Damron, Kim S. ; Datta, Sukdeb ; Deer, Timothy R. ; Diwan, Sudhir ; Eriator, Ike ; Falco, Frank J E ; Fellows, Bert ; Geffert, Stephanie ; Gharibo, Christopher G. ; Glaser, Scott E. ; Grider, Jay S. ; Hameed, Haroon ; Hameed, Mariam ; Hansen, Hans ; Harned, Michael E. ; Hayek, Salim M. ; Helm, Standiford ; Hirsch, Joshua A. ; Janata, Jeffrey W. ; Kaye, Alan D. ; Kaye, Adam M. ; Kloth, David S. ; Koyyalagunta, Dhanalakshmi ; Lee, Marion ; Malla, Yogesh ; Manchikanti, Kavita N. ; McManus, Carla D. ; Pampati, Vidyasagar ; Parr, Allan T. ; Pasupuleti, Ramarao ; Patel, Vikram B. ; Sehgal, Nalini ; Silverman, Sanford M. ; Singh, Vijay ; Smith, Howard S. ; Snook, Lee T. ; Solanki, Daneshvari R. ; Tracy, Deborah H. ; Vallejo, Ricardo ; Wargo, Bradley W. ; American Society of Interventional Pain Physicians, Society of Interventional Pain Physicians. / American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain : Part I--evidence assessment. In: Pain Physician. 2012 ; Vol. 15, No. 3 Suppl.
@article{05a8edee551b4be2b4b30a5a296e7161,
title = "American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I--evidence assessment.",
abstract = "Opioid abuse has continued to increase at an alarming rate since the 1990 s. As documented by different medical specialties, medical boards, advocacy groups, and the Drug Enforcement Administration, available evidence suggests a wide variance in chronic opioid therapy of 90 days or longer in chronic non-cancer pain. Part 1 describes evidence assessment. The objectives of opioid guidelines as issued by the American Society of Interventional Pain Physicians (ASIPP) are to provide guidance for the use of opioids for the treatment of chronic non-cancer pain, to produce consistency in the application of an opioid philosophy among the many diverse groups involved, to improve the treatment of chronic non-cancer pain, and to reduce the incidence of abuse and drug diversion. The focus of these guidelines is to curtail the abuse of opioids without jeopardizing non-cancer pain management with opioids. 1) There is good evidence that non-medical use of opioids is extensive; one-third of chronic pain patients may not use prescribed opioids as prescribed or may abuse them, and illicit drug use is significantly higher in these patients. 2) There is good evidence that opioid prescriptions are increasing rapidly, as the majority of prescriptions are from non-pain physicians, many patients are on long-acting opioids, and many patients are provided with combinations of long-acting and short-acting opioids. 3) There is good evidence that the increased supply of opioids, use of high dose opioids, doctor shoppers, and patients with multiple comorbid factors contribute to the majority of the fatalities. 4) There is fair evidence that long-acting opioids and a combination of long-acting and short-acting opioids contribute to increasing fatalities and that even low-doses of 40 mg or 50 mg of daily morphine equivalent doses may be responsible for emergency room admissions with overdoses and deaths. 5) There is good evidence that approximately 60{\%} of fatalities originate from opioids prescribed within the guidelines, with approximately 40{\%} of fatalities occurring in 10{\%} of drug abusers. 6) The short-term effectiveness of opioids is fair, whereas the long-term effectiveness of opioids is limited due to a lack of long-term (> 3 months) high quality studies, with fair evidence with no significant difference between long-acting and short-acting opioids. 7) Among the individual drugs, most opioids have fair evidence for short-term and limited evidence for long-term due to a lack of quality studies. 8) The evidence for the effectiveness and safety of chronic opioid therapy in the elderly for chronic non-cancer pain is fair for short-term and limited for long-term due to lack of high quality studies; limited in children and adolescents and patients with comorbid psychological disorders due to lack of quality studies; and the evidence is poor in pregnant women. 9) There is limited evidence for reliability and accuracy of screening tests for opioid abuse due to lack of high quality studies. 10) There is fair evidence to support the identification of patients who are non-compliant or abusing prescription drugs or illicit drugs through urine drug testing and prescription drug monitoring programs, both of which can reduce prescription drug abuse or doctor shopping. DISCLAIMER: The guidelines are based on the best available evidence and do not constitute inflexible treatment recommendations. Due to the changing body of evidence, this document is not intended to be a {"}standard of care.{"}",
author = "Laxmaiah Manchikanti and Salahadin Abdi and Sairam Atluri and Balog, {Carl C.} and Benyamin, {Ramsin M.} and Boswell, {Mark V.} and Brown, {Keith R.} and Bruel, {Brian M.} and Bryce, {David A.} and Burks, {Patricia A.} and Burton, {Allen W.} and Calodney, {Aaron K.} and Caraway, {David L.} and Cash, {Kimberly A.} and Christo, {Paul J.} and Damron, {Kim S.} and Sukdeb Datta and Deer, {Timothy R.} and Sudhir Diwan and Ike Eriator and Falco, {Frank J E} and Bert Fellows and Stephanie Geffert and Gharibo, {Christopher G.} and Glaser, {Scott E.} and Grider, {Jay S.} and Haroon Hameed and Mariam Hameed and Hans Hansen and Harned, {Michael E.} and Hayek, {Salim M.} and Standiford Helm and Hirsch, {Joshua A.} and Janata, {Jeffrey W.} and Kaye, {Alan D.} and Kaye, {Adam M.} and Kloth, {David S.} and Dhanalakshmi Koyyalagunta and Marion Lee and Yogesh Malla and Manchikanti, {Kavita N.} and McManus, {Carla D.} and Vidyasagar Pampati and Parr, {Allan T.} and Ramarao Pasupuleti and Patel, {Vikram B.} and Nalini Sehgal and Silverman, {Sanford M.} and Vijay Singh and Smith, {Howard S.} and Snook, {Lee T.} and Solanki, {Daneshvari R.} and Tracy, {Deborah H.} and Ricardo Vallejo and Wargo, {Bradley W.} and {American Society of Interventional Pain Physicians}, {Society of Interventional Pain Physicians}",
year = "2012",
month = "7",
language = "English (US)",
volume = "15",
journal = "Pain Physician",
issn = "1533-3159",
publisher = "Association of Pain Management Anesthesiologists",
number = "3 Suppl",

}

TY - JOUR

T1 - American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain

T2 - Part I--evidence assessment.

AU - Manchikanti, Laxmaiah

AU - Abdi, Salahadin

AU - Atluri, Sairam

AU - Balog, Carl C.

AU - Benyamin, Ramsin M.

AU - Boswell, Mark V.

AU - Brown, Keith R.

AU - Bruel, Brian M.

AU - Bryce, David A.

AU - Burks, Patricia A.

AU - Burton, Allen W.

AU - Calodney, Aaron K.

AU - Caraway, David L.

AU - Cash, Kimberly A.

AU - Christo, Paul J.

AU - Damron, Kim S.

AU - Datta, Sukdeb

AU - Deer, Timothy R.

AU - Diwan, Sudhir

AU - Eriator, Ike

AU - Falco, Frank J E

AU - Fellows, Bert

AU - Geffert, Stephanie

AU - Gharibo, Christopher G.

AU - Glaser, Scott E.

AU - Grider, Jay S.

AU - Hameed, Haroon

AU - Hameed, Mariam

AU - Hansen, Hans

AU - Harned, Michael E.

AU - Hayek, Salim M.

AU - Helm, Standiford

AU - Hirsch, Joshua A.

AU - Janata, Jeffrey W.

AU - Kaye, Alan D.

AU - Kaye, Adam M.

AU - Kloth, David S.

AU - Koyyalagunta, Dhanalakshmi

AU - Lee, Marion

AU - Malla, Yogesh

AU - Manchikanti, Kavita N.

AU - McManus, Carla D.

AU - Pampati, Vidyasagar

AU - Parr, Allan T.

AU - Pasupuleti, Ramarao

AU - Patel, Vikram B.

AU - Sehgal, Nalini

AU - Silverman, Sanford M.

AU - Singh, Vijay

AU - Smith, Howard S.

AU - Snook, Lee T.

AU - Solanki, Daneshvari R.

AU - Tracy, Deborah H.

AU - Vallejo, Ricardo

AU - Wargo, Bradley W.

AU - American Society of Interventional Pain Physicians, Society of Interventional Pain Physicians

PY - 2012/7

Y1 - 2012/7

N2 - Opioid abuse has continued to increase at an alarming rate since the 1990 s. As documented by different medical specialties, medical boards, advocacy groups, and the Drug Enforcement Administration, available evidence suggests a wide variance in chronic opioid therapy of 90 days or longer in chronic non-cancer pain. Part 1 describes evidence assessment. The objectives of opioid guidelines as issued by the American Society of Interventional Pain Physicians (ASIPP) are to provide guidance for the use of opioids for the treatment of chronic non-cancer pain, to produce consistency in the application of an opioid philosophy among the many diverse groups involved, to improve the treatment of chronic non-cancer pain, and to reduce the incidence of abuse and drug diversion. The focus of these guidelines is to curtail the abuse of opioids without jeopardizing non-cancer pain management with opioids. 1) There is good evidence that non-medical use of opioids is extensive; one-third of chronic pain patients may not use prescribed opioids as prescribed or may abuse them, and illicit drug use is significantly higher in these patients. 2) There is good evidence that opioid prescriptions are increasing rapidly, as the majority of prescriptions are from non-pain physicians, many patients are on long-acting opioids, and many patients are provided with combinations of long-acting and short-acting opioids. 3) There is good evidence that the increased supply of opioids, use of high dose opioids, doctor shoppers, and patients with multiple comorbid factors contribute to the majority of the fatalities. 4) There is fair evidence that long-acting opioids and a combination of long-acting and short-acting opioids contribute to increasing fatalities and that even low-doses of 40 mg or 50 mg of daily morphine equivalent doses may be responsible for emergency room admissions with overdoses and deaths. 5) There is good evidence that approximately 60% of fatalities originate from opioids prescribed within the guidelines, with approximately 40% of fatalities occurring in 10% of drug abusers. 6) The short-term effectiveness of opioids is fair, whereas the long-term effectiveness of opioids is limited due to a lack of long-term (> 3 months) high quality studies, with fair evidence with no significant difference between long-acting and short-acting opioids. 7) Among the individual drugs, most opioids have fair evidence for short-term and limited evidence for long-term due to a lack of quality studies. 8) The evidence for the effectiveness and safety of chronic opioid therapy in the elderly for chronic non-cancer pain is fair for short-term and limited for long-term due to lack of high quality studies; limited in children and adolescents and patients with comorbid psychological disorders due to lack of quality studies; and the evidence is poor in pregnant women. 9) There is limited evidence for reliability and accuracy of screening tests for opioid abuse due to lack of high quality studies. 10) There is fair evidence to support the identification of patients who are non-compliant or abusing prescription drugs or illicit drugs through urine drug testing and prescription drug monitoring programs, both of which can reduce prescription drug abuse or doctor shopping. DISCLAIMER: The guidelines are based on the best available evidence and do not constitute inflexible treatment recommendations. Due to the changing body of evidence, this document is not intended to be a "standard of care."

AB - Opioid abuse has continued to increase at an alarming rate since the 1990 s. As documented by different medical specialties, medical boards, advocacy groups, and the Drug Enforcement Administration, available evidence suggests a wide variance in chronic opioid therapy of 90 days or longer in chronic non-cancer pain. Part 1 describes evidence assessment. The objectives of opioid guidelines as issued by the American Society of Interventional Pain Physicians (ASIPP) are to provide guidance for the use of opioids for the treatment of chronic non-cancer pain, to produce consistency in the application of an opioid philosophy among the many diverse groups involved, to improve the treatment of chronic non-cancer pain, and to reduce the incidence of abuse and drug diversion. The focus of these guidelines is to curtail the abuse of opioids without jeopardizing non-cancer pain management with opioids. 1) There is good evidence that non-medical use of opioids is extensive; one-third of chronic pain patients may not use prescribed opioids as prescribed or may abuse them, and illicit drug use is significantly higher in these patients. 2) There is good evidence that opioid prescriptions are increasing rapidly, as the majority of prescriptions are from non-pain physicians, many patients are on long-acting opioids, and many patients are provided with combinations of long-acting and short-acting opioids. 3) There is good evidence that the increased supply of opioids, use of high dose opioids, doctor shoppers, and patients with multiple comorbid factors contribute to the majority of the fatalities. 4) There is fair evidence that long-acting opioids and a combination of long-acting and short-acting opioids contribute to increasing fatalities and that even low-doses of 40 mg or 50 mg of daily morphine equivalent doses may be responsible for emergency room admissions with overdoses and deaths. 5) There is good evidence that approximately 60% of fatalities originate from opioids prescribed within the guidelines, with approximately 40% of fatalities occurring in 10% of drug abusers. 6) The short-term effectiveness of opioids is fair, whereas the long-term effectiveness of opioids is limited due to a lack of long-term (> 3 months) high quality studies, with fair evidence with no significant difference between long-acting and short-acting opioids. 7) Among the individual drugs, most opioids have fair evidence for short-term and limited evidence for long-term due to a lack of quality studies. 8) The evidence for the effectiveness and safety of chronic opioid therapy in the elderly for chronic non-cancer pain is fair for short-term and limited for long-term due to lack of high quality studies; limited in children and adolescents and patients with comorbid psychological disorders due to lack of quality studies; and the evidence is poor in pregnant women. 9) There is limited evidence for reliability and accuracy of screening tests for opioid abuse due to lack of high quality studies. 10) There is fair evidence to support the identification of patients who are non-compliant or abusing prescription drugs or illicit drugs through urine drug testing and prescription drug monitoring programs, both of which can reduce prescription drug abuse or doctor shopping. DISCLAIMER: The guidelines are based on the best available evidence and do not constitute inflexible treatment recommendations. Due to the changing body of evidence, this document is not intended to be a "standard of care."

UR - http://www.scopus.com/inward/record.url?scp=84869831249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869831249&partnerID=8YFLogxK

M3 - Article

C2 - 22786448

AN - SCOPUS:84869831249

VL - 15

JO - Pain Physician

JF - Pain Physician

SN - 1533-3159

IS - 3 Suppl

ER -